197 related articles for article (PubMed ID: 24334295)
1. The PDK1 master kinase is over-expressed in acute myeloid leukemia and promotes PKC-mediated survival of leukemic blasts.
Zabkiewicz J; Pearn L; Hills RK; Morgan RG; Tonks A; Burnett AK; Darley RL
Haematologica; 2014 May; 99(5):858-64. PubMed ID: 24334295
[TBL] [Abstract][Full Text] [Related]
2. The role of PKC and PDK1 in monocyte lineage specification by Ras.
Pearn L; Fisher J; Burnett AK; Darley RL
Blood; 2007 May; 109(10):4461-9. PubMed ID: 17255356
[TBL] [Abstract][Full Text] [Related]
3. Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1.
Najafov A; Sommer EM; Axten JM; Deyoung MP; Alessi DR
Biochem J; 2011 Jan; 433(2):357-69. PubMed ID: 21087210
[TBL] [Abstract][Full Text] [Related]
4. Targeting PDK1 with dichloroacetophenone to inhibit acute myeloid leukemia (AML) cell growth.
Qin L; Tian Y; Yu Z; Shi D; Wang J; Zhang C; Peng R; Chen X; Liu C; Chen Y; Huang W; Deng W
Oncotarget; 2016 Jan; 7(2):1395-407. PubMed ID: 26593251
[TBL] [Abstract][Full Text] [Related]
5. Akt is efficiently activated by PIF-pocket- and PtdIns(3,4,5)P3-dependent mechanisms leading to resistance to PDK1 inhibitors.
Najafov A; Shpiro N; Alessi DR
Biochem J; 2012 Dec; 448(2):285-95. PubMed ID: 23030823
[TBL] [Abstract][Full Text] [Related]
6. Genetic and pharmacological inhibition of PDK1 in cancer cells: characterization of a selective allosteric kinase inhibitor.
Nagashima K; Shumway SD; Sathyanarayanan S; Chen AH; Dolinski B; Xu Y; Keilhack H; Nguyen T; Wiznerowicz M; Li L; Lutterbach BA; Chi A; Paweletz C; Allison T; Yan Y; Munshi SK; Klippel A; Kraus M; Bobkova EV; Deshmukh S; Xu Z; Mueller U; Szewczak AA; Pan BS; Richon V; Pollock R; Blume-Jensen P; Northrup A; Andersen JN
J Biol Chem; 2011 Feb; 286(8):6433-48. PubMed ID: 21118801
[TBL] [Abstract][Full Text] [Related]
7. The FLT3 internal tandem duplication mutation is a secondary target of the aurora B kinase inhibitor AZD1152-HQPA in acute myelogenous leukemia cells.
Grundy M; Seedhouse C; Shang S; Richardson J; Russell N; Pallis M
Mol Cancer Ther; 2010 Mar; 9(3):661-72. PubMed ID: 20159992
[TBL] [Abstract][Full Text] [Related]
8. Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells.
Weisberg E; Banerji L; Wright RD; Barrett R; Ray A; Moreno D; Catley L; Jiang J; Hall-Meyers E; Sauveur-Michel M; Stone R; Galinsky I; Fox E; Kung AL; Griffin JD
Blood; 2008 Apr; 111(7):3723-34. PubMed ID: 18184863
[TBL] [Abstract][Full Text] [Related]
9. Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells.
Renner AG; Dos Santos C; Recher C; Bailly C; Créancier L; Kruczynski A; Payrastre B; Manenti S
Blood; 2009 Jul; 114(3):659-62. PubMed ID: 19458358
[TBL] [Abstract][Full Text] [Related]
10. Protein kinase C-mediated phosphorylation of the leukemia-associated HOXA9 protein impairs its DNA binding ability and induces myeloid differentiation.
Vijapurkar U; Fischbach N; Shen W; Brandts C; Stokoe D; Lawrence HJ; Largman C
Mol Cell Biol; 2004 May; 24(9):3827-37. PubMed ID: 15082777
[TBL] [Abstract][Full Text] [Related]
11. Protein kinase C theta (PKCtheta)-dependent phosphorylation of PDK1 at Ser504 and Ser532 contributes to palmitate-induced insulin resistance.
Wang C; Liu M; Riojas RA; Xin X; Gao Z; Zeng R; Wu J; Dong LQ; Liu F
J Biol Chem; 2009 Jan; 284(4):2038-44. PubMed ID: 19047061
[TBL] [Abstract][Full Text] [Related]
12. Further evidence that 3-phosphoinositide-dependent protein kinase-1 (PDK1) is required for the stability and phosphorylation of protein kinase C (PKC) isoforms.
Balendran A; Hare GR; Kieloch A; Williams MR; Alessi DR
FEBS Lett; 2000 Nov; 484(3):217-23. PubMed ID: 11078882
[TBL] [Abstract][Full Text] [Related]
13. Constitutive c-jun N-terminal kinase activity in acute myeloid leukemia derives from Flt3 and affects survival and proliferation.
Hartman AD; Wilson-Weekes A; Suvannasankha A; Burgess GS; Phillips CA; Hincher KJ; Cripe LD; Boswell HS
Exp Hematol; 2006 Oct; 34(10):1360-76. PubMed ID: 16982329
[TBL] [Abstract][Full Text] [Related]
14. Genetic inactivation or pharmacological inhibition of Pdk1 delays development and inhibits metastasis of Braf(V600E)::Pten(-/-) melanoma.
Scortegagna M; Ruller C; Feng Y; Lazova R; Kluger H; Li JL; De SK; Rickert R; Pellecchia M; Bosenberg M; Ronai ZA
Oncogene; 2014 Aug; 33(34):4330-9. PubMed ID: 24037523
[TBL] [Abstract][Full Text] [Related]
15. In vivo role of the phosphate groove of PDK1 defined by knockin mutation.
Collins BJ; Deak M; Murray-Tait V; Storey KG; Alessi DR
J Cell Sci; 2005 Nov; 118(Pt 21):5023-34. PubMed ID: 16219676
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia.
Cristóbal I; Garcia-Orti L; Cirauqui C; Cortes-Lavaud X; García-Sánchez MA; Calasanz MJ; Odero MD
Haematologica; 2012 Apr; 97(4):543-50. PubMed ID: 22133779
[TBL] [Abstract][Full Text] [Related]
17. Protein kinase C(mu) regulation of the JNK pathway is triggered via phosphoinositide-dependent kinase 1 and protein kinase C(epsilon).
Brändlin I; Eiseler T; Salowsky R; Johannes FJ
J Biol Chem; 2002 Nov; 277(47):45451-7. PubMed ID: 12223477
[TBL] [Abstract][Full Text] [Related]
18. Phosphoinositide-dependent protein kinase-1 (PDK1)-independent activation of the protein kinase C substrate, protein kinase D.
Wood CD; Kelly AP; Matthews SA; Cantrell DA
FEBS Lett; 2007 Jul; 581(18):3494-8. PubMed ID: 17617409
[TBL] [Abstract][Full Text] [Related]
19. Elevated PIM2 gene expression is associated with poor survival of patients with acute myeloid leukemia.
Kapelko-Slowik K; Owczarek TB; Grzymajlo K; Urbaniak-Kujda D; Jazwiec B; Slowik M; Kuliczkowski K; Ugorski M
Leuk Lymphoma; 2016 Sep; 57(9):2140-9. PubMed ID: 26764044
[TBL] [Abstract][Full Text] [Related]
20. PDK1 protein phosphorylation at Thr354 by murine protein serine-threonine kinase 38 contributes to negative regulation of PDK1 protein activity.
Seong HA; Jung H; Manoharan R; Ha H
J Biol Chem; 2012 Jun; 287(25):20811-22. PubMed ID: 22544756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
